Late thrombosis following treatment of in‐stent restenosis with drug‐eluting stents after discontinuation of antiplatelet therapy

• Published in: Catheterization and cardiovascular interventions Vol. 65; no. 4; pp. 520 - 524
• Main Authors: Waters, Richard E., Kandzari, David E., Phillips, Harry R., Crawford, Lawrence E., Sketch, Michael H.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01-08-2005
• Subjects: Adult; Aged; angioplasty; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation - adverse effects; Coated Materials, Biocompatible - therapeutic use; Coronary Angiography; Coronary Artery Disease - therapy; Coronary Restenosis - diagnostic imaging; Coronary Restenosis - therapy; coronary thrombosis; Coronary Thrombosis - diagnostic imaging; Coronary Thrombosis - etiology; Humans; Male; Middle Aged; Myocardial Infarction - diagnostic imaging; Myocardial Infarction - therapy; percutaneous coronary; platelet aggregation inhibitors; Platelet Aggregation Inhibitors - therapeutic use; Postoperative Complications - diagnostic imaging; Postoperative Complications - etiology; sirolimus; Sirolimus - therapeutic use; Stents - adverse effects; Time Factors; transluminal
• ISSN: 1522-1946; 1522-726X
• DOI: 10.1002/ccd.20428

Drug‐eluting stent usage has become commonplace for the percutaneous treatment of de novo coronary lesions, but the safety and efficacy profile for their evolving usage in restenotic lesions is largely unknown. We report three cases of angiographically confirmed drug‐eluting stent thrombosis following treatment of restenotic lesions that occurred late (193, 237, and 535 days) and shortly after interruption of antiplatelet therapy. All three patients suffered ST elevation myocardial infarction, and there was one death. Further studies are necessary to better define the associated risk and ideal duration of antiplatelet therapy necessary in this cohort of patients with restenotic lesions. © 2005 Wiley‐Liss, Inc.